Pfizer CEO highlights savings, leadership changes, and acquisition-driven growth amid significant revenue loss challenges ...

Barré for every million doses given.

Pfizer has had a difficult time in recent years as demand for its coronavirus products declined. The company’s share price has reflected the tough times, falling more than 50% over three years.

In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on Pfizer (PFE – Research Report), with a price target of ...

Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Pfizer (PFE – Research Report) and keeping the price target at $36.00.Stay ...

Monday, three Big Pharma leaders took center stage and addressed concerns about future patent expirations head-on.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Then, this is the segment with the strongest focus in Pfizer's pipeline. If we take a look at the top 10 products in 2023, the ranking is still led by Comirnaty (19% weight), despite the drop in ...

Pfizer’s sales excluding Covid-19 products have grown in double-digits over the last couple of quarters. Pfizer is seeing a strong uptick in Vyndaqel and Abrysvo and a continued growth in ...